Pre-Surgery Radiation for Early-Stage Breast Cancer
Trial Summary
What is the purpose of this trial?
This pilot clinical trial studies intensity-modulated accelerated partial breast irradiation (APBI) before surgery in treating older patients with estrogen receptor positive or progesterone receptor positive stage I breast cancer. APBI is a specialized type of radiation therapy that delivers a high dose of radiation directly to the tumor may kill more tumor cells and cause less damage to normal tissue. Giving radiation therapy before surgery may make the tumor smaller and reduce the amount of normal tissue that needs to be removed.
Research Team
Sasha Beyer, MD
Principal Investigator
Ohio State University Comprehensive Cancer Center
Eligibility Criteria
This trial is for women over 50 with stage I breast cancer that's hormone responsive and hasn't spread. They must be able to have an MRI, lie prone during treatment, and agree to surgery after radiation. Excluded are those with large tumors (>3cm), prior breast treatments, or certain other cancers within the last 5 years.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Radiation
Participants undergo image-guided intensity-modulated accelerated partial breast irradiation (APBI) twice daily in the prone position
Surgery
Participants undergo lumpectomy within 4-6 weeks post-APBI
Follow-up
Participants are monitored for safety and effectiveness after treatment
Treatment Details
Interventions
- Accelerated Partial Breast Irradiation
- Image-Guided Radiation Therapy
- Intensity-Modulated Radiation Therapy
- Therapeutic Conventional Surgery
Accelerated Partial Breast Irradiation is already approved in United States, European Union, Canada for the following indications:
- Early-stage breast cancer
- Ductal carcinoma in situ (DCIS)
- Stage I or II breast cancer
- Early-stage breast cancer
- Ductal carcinoma in situ (DCIS)
- Stage I or II breast cancer
- Early-stage breast cancer
- Ductal carcinoma in situ (DCIS)
- Stage I or II breast cancer
Find a Clinic Near You
Who Is Running the Clinical Trial?
Ohio State University Comprehensive Cancer Center
Lead Sponsor